Results 51 to 60 of about 51,092 (200)

Data envelopment analysis of cooperative efficiency and members’ deposit in Ogun state, Nigeria

open access: yesStudia Ekonomiczne i Regionalne
Cooperatives offer significant opportunities for economic empowerment of people in difficult economic climates. However, concerns exist in literature on the efficiency level of these organisations in relation to members’ deposits and financial-related ...
Sofoluwe Nurudeen Afolabi   +2 more
doaj   +1 more source

Factors associated with anti-drug antibody production in ankylosing spondylitis patients treated with the infliximab biosimilar CT-P13

open access: yesJournal of Rheumatic Diseases
Objective: CT-P13, a biosimilar of infliximab, is widely used for treating ankylosing spondylitis (AS). However, the formation of anti-drug antibodies (ADAs) can reduce its efficacy.
Yongbum Kim   +5 more
doaj   +1 more source

P13 Unmapped Reads

open access: yes, 2018
P13 Unmapped ...
Monica B. Arniella (5011919)   +5 more
core   +1 more source

t(7;12)(q36;p13) [PDF]

open access: yes, 2004
Review on t(7;12)(q36;p13), with data on clinics, and the genes ...
HB Beverloo   +3 more
core   +1 more source

Loan repayment behavior of beneficiary farmers in primary agricultural cooperative societies in Haryana (India)

open access: yesStudia Ekonomiczne i Regionalne
The study examined the loan repayment behavior of beneficiary farmers in Primary Agricultural Cooperative Societies in the State of Haryana, India.
Singh Suninder   +3 more
doaj   +1 more source

Evaluation of novel cardiovascular risk calculators in patients with rheumatoid arthritis

open access: yesJournal of Rheumatic Diseases
Objective: CT-P13, a biosimilar of infliximab, is widely used for treating ankylosing spondylitis (AS). However, the formation of anti-drug antibodies (ADAs) can reduce its efficacy.
Dionicio Angel Galarza-Delgado   +8 more
doaj   +1 more source

Anti-drug antibodies and rheumatoid factor level in patients with rheumatoid arthritis using the infliximab biosimilar CT-P13

open access: yesBMC Rheumatology, 2022
Background This study evaluated the existence of anti-drug antibodies (ADAs) before and 52 weeks after switching from intravenous infliximab (IFX) to intravenous CT-P13 in patients with rheumatoid arthritis (RA).
Hideo Sakane   +9 more
doaj   +1 more source

t(3;4)(q27;p13) [PDF]

open access: yes, 1998
Review on t(3;4)(q27;p13), with data on clinics, and the genes ...
Daudignon, A
core   +1 more source

Pharmacokinetic comparison of subcutaneously administered CT‐P13 (biosimilar of infliximab) via autoinjector and pre‐filled syringe in healthy participants

open access: yesClinical and Translational Science
CT‐P13, a biosimilar of infliximab, is used to treat inflammatory diseases that arise from immune system complications, resulting in excessive and persistent inflammation.
Ye Chan Park   +6 more
doaj   +1 more source

A novel nitrogenous coumarin: The promising antiviral therapy against white spot syndrome virus in the culture of shrimp seedlings

open access: yesAquaculture Reports
White spot disease (WSD), attributed to the white spot syndrome virus (WSSV), represents a substantial danger to the international shrimp sector, resulting in considerable losses in both production and economic terms. Nevertheless, there are currently no
Huan Wang   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy